

Press release 2026-03-27

## AcuCort publishes newsletter with CEO update

AcuCort has published its newsletter for March 2026. The newsletter features a CEO statement by Jonas Jönmark as well as two articles: one on the company now operating its pharmacovigilance system in-house, and one on Zeqmelits® being suitable for more indications than acute allergic reaction, where AcuCort sees opportunities primarily within two areas.

The newsletter is available here: <https://bit.ly/acucort-spring-2026>

**For further information:**

Jonas Jönmark, CEO, AcuCort AB

Phone: 070 365 5400

E-mail: [jonas.jonmark@acucort.se](mailto:jonas.jonmark@acucort.se)

**About AcuCort AB (publ)**

AcuCort has developed and is commercializing Zeqmelit®, a new rapidly dissolving oral film placed on the tongue, based on the well-known cortisone substance dexamethasone. The drug is a smart product in a new, innovative, patented, and user-friendly administration form primarily for the treatment of severe and acute allergic reactions, croup in children, nausea and vomiting during chemotherapy, and for the treatment of patients with COVID-19 requiring supplemental oxygen therapy. Zeqmelit® is approved in Sweden, Denmark, Norway, and Finland. AcuCort (ticker: ACUC) is listed on the Spotlight Stock Market. Visit [www.acucort.se](http://www.acucort.se) for more information.